ZIOPHARM Oncology, Inc. and Intrexon Corporation Announce Presentation of Data Highlighting Versatility of Novel Gene Expression and Control Technology
Published: Oct 22, 2013
BOSTON and GERMANTOWN, Md., Oct. 21, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the discovery and development of new cancer therapies, and Intrexon Corporation (NYSE:XON), a leader in synthetic biology, today announced the presentation of preclinical data from three studies that highlight the versatility of the novel gene expression and control technology used to develop ZIOPHARM's synthetic biology pipeline in oncology. The results were presented at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is taking place October 19-23, 2013, in Boston.
Help employers find you! Check out all the jobs and post your resume.